

KENYA

Support for Inactivated Polio Virus Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme

1. Country:	Kenya						
2. Vaccine grant number:	15-KEN-08h-Y, 1518-KEN-25c-X, 19-KEN-25c-X, 20-KEN-25c-X						
3. Date of Decision Letter:	30-Sep-2019						
4. Date of the Partnership Framework Agreement:	25 November 2014						
5. Programme title:	New Vaccine Support (NVS), Inactivated Polio Virus, Routine						
6. Vaccine type:	Inactivated Polio Virus						
7. Requested product presentation and formulation of vaccine:	Inactivated Polio Vaccine, 10 doses per vial, LIQUID						
8. Programme Duration:¹	2015-2020						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2015-2019	2020	2021	2022	2023	2024	Total²
Programme Budget (US\$)	7,528,665	3,546,000	-	-	-	-	11,074,665
10. Vaccine introduction grant							
	Approval						
	Year	Grant Number					Amount (US\$)
	2015	15-KEN-08h-Y					1,263,500
	Disbursement						
	Disbursement date						Amount (US\$)
	07 August, 2015						1,263,500
11. Product switch grant							
	Not applicable						
	Approval						
	<i>Approval</i>						
	Year	Grant Number					Amount (US\$)
	-	-					-
	-	-					-
	Disbursement						
	Disbursement date						Amount (US\$)

¹ This is the entire duration of the programme.

² This is the total amount endorsed by Gavi for the entire duration of the programme.

³ This is the amount that Gavi has approved.

	-
	-
	-

11. Indicative Annual Amounts:³ (subject to the terms of the Partnership Framework Agreement, if applicable)

Type of supplies to be purchased with Gavi funds	2015-2019	2020	2021
Number of vaccine doses		1,597,000	-
Annual Amounts (US\$)	7,528,665	3,546,000	-

12. Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.

13. Self-procurement: Not applicable

14. Co-financing obligations:

Not applicable

Gavi's usual co-financing requirements do not apply to IPV. However, the Country is encouraged to contribute to vaccine and/or supply costs for IPV.

15. Additional Reporting Requirements:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received 	Quarterly 15 May 2020
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

16. Financial clarifications: Not applicable

17. Other:

Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.

Signed by,
On behalf of Gavi



Thabani Maphosa,
Managing Director, Country Programmes
30 September 2019